These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17634550)

  • 1. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
    Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
    Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
    Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
    Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
    Nisancioglu MH; Betsholtz C; Genové G
    Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
    Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
    Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
    Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
    Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM; Paoni SF
    Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
    Apte SM; Fan D; Killion JJ; Fidler IJ
    Clin Cancer Res; 2004 Feb; 10(3):897-908. PubMed ID: 14871965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
    Dang DT; Chun SY; Burkitt K; Abe M; Chen S; Havre P; Mabjeesh NJ; Heath EI; Vogelzang NJ; Cruz-Correa M; Blayney DW; Ensminger WD; St Croix B; Dang NH; Dang LH
    Cancer Res; 2008 Mar; 68(6):1872-80. PubMed ID: 18339868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy.
    Bagley RG; Weber W; Rouleau C; Teicher BA
    Cancer Res; 2005 Nov; 65(21):9741-50. PubMed ID: 16266995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.